Isoflavones in treating watchful waiting benign prostate hyperplasia: A double-blinded, randomized controlled trial

Journal of Alternative and Complementary Medicine

Volumn 18, Issue 1, 2012, Pages 54-60

  Wong, William C W ^a   Wong, Eliza L Y ^b   Li, Han ^b   You, Joyce H ^c   Ho, Suzanne ^b   Woo, Jean ^b,d   Hui, Elsie ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e SHATIN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ISOFLAVONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; BLADDER EMPTYING; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GOUT; HONG KONG; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KIDNEY FUNCTION; LIBIDO DISORDER; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PAIN; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN DISEASE; URINE FLOW RATE;

DIAGNOSTIC TECHNIQUES, UROLOGICAL; DOUBLE-BLIND METHOD; HUMANS; ISOFLAVONES; MALE; MIDDLE AGED; PHYTOTHERAPY; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84863046163     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2010.0077     Document Type: Review

References (32)

1. Lee C, Cockett A, Cussenot K, et al. Regulation of prostate growth. In: Proceedings of the Fifth International Consultation on Benign Prostatic Hyperplasia. Birmingham, UK: Health Publications, Ltd., 2001, 79 & 106.
2. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978;15:340.
3. Dreikorn K. Complementary and alternative medicine in urology. BJU Int 2005;96:1177-1184. (Pubitemid 41736975)
4. Chan JM, Elkin EP, Silva SJ, et al. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. Urology 2005;66:1223-1228. (Pubitemid 41797295)
5. Lee MM, Chang JS, Jacobs B, et al. Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations. Am J Public Health 2002;92:1606-1609.
6. Wong TW, Wong SL, Donnan SP. Prevalence and determinants of the use of traditional Chinese medicine in Hong Kong. Asia Pac J Public Health 1995;8:167-170.
7. Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2009;2:CD001423.
8. Wilt T, MacDonald R, Ishani A, et al. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000;2: CD001042.
9. Wilt T, Ishani A, MacDonald R, et al. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;2:CD001043.
10. Wilt T, Ishani A. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;1:CD001044.
11. Wong SY, Lau WW, Leung PC, et al. The association between isoflavone and lower urinary tract symptoms in elderly men. Br J Nutr 2007;98:1237-1242. (Pubitemid 350193791)
12. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha-re-ductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995;147:295-302.
13. Keung WM. Dietary estrogenic isoflavones are potent inhibitors of beta-hydroxysteroid dehydrogenase of P. testos-teronii. Biochem Biophys Res Commun 1995;215:1137-1144.
14. Campbell DR, Kurzer MS. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J Steroid Biochem Mol Biol 1993;46:381-388. (Pubitemid 23284496)
15. Matzkin H, Soloway MS. Immunohistochemical evidence of the existence and localization of aromatase in human pros-tatic tissues. Prostate 1992;21:309-314. (Pubitemid 23045293)
16. Wang TT, Sathyamoorthy N, Phang JM. Molecular effects of genistein on estrogen receptor mediated pathways. Carci-nogenesis 1996;17:271-275. (Pubitemid 26091305)
17. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993;342:1209-1210. (Pubitemid 23331713)
18. Morton MS, Chan PS, Cheng C, et al. Lignans and iso-flavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997;32:122-128. (Pubitemid 27280356)
19. Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer: Geographical distribution and time-trends. Acta Oncol 1991;30:133-140.
20. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998;9:553-557. (Pubitemid 29046127)
21. American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia updated 2003. Online document at: www.auanet.org/content/ guidelines-and-quality-care/clinical-guidelines.cfm?sub= bph Accessed May 8, 2009.
22. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996;155:1251-1259. (Pubitemid 26392086)
23. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: A population based survey of urinary symptoms. J Urol 1993;150:85-89. (Pubitemid 23175978)
24. Shi R, Xie Q, Gang X, et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized trial in Shanghai, China. J Urol 2008;179:610-615.
25. Cassidy A. Potential risks and benefits of phytoestrogen-rich diets. Int J Vitam Nutr Res 2003;73:120-126. (Pubitemid 36427779)
26. Griffiths K, Morton MS, Denis L. Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer. Eur Urol 1999;35:443-455. (Pubitemid 29229547)
27. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004;59:141-147. (Pubitemid 38481225)
28. Lam CL, Gandek B, Ren XS, et al. Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 Health Survey. J Clin Epidemiol 1998;51:1139-1147. (Pubitemid 28527169)
29. Hebert JR, Ockene IS, Hurley TG, et al. Development and testing of a seven-day dietary recall. Dietary Assessment Working Group of the Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). J Clin Epidemiol 1997;50:925-937.
30. Abbott Laboratories. HYTRIN-terazosin hydrochloride tablet. North Chicago, IL. 2009. updated 2009. Online document at: www.rxabbott.com/u4- prescribing-info.cfm Accessed May 8, 2009.
31. Michel MC, Goepel M. Treatment satisfaction of patients with lower urinary tract symptoms: Randomised controlled trials vs. real life practice. Eur Urol 2000;38:40-47.
32. de la Rosette J, Madersbacher S, Alivizatos G, et al. Guidelines on Benign Prostatic Hyperplasia. European Association of Urology. 2006. Online document at: www.urotoday.com/prod/pdf/eau/BPH-August-2004.pdf Accessed May 8, 2009.